daily. This achieved complete remission of the disease; the haematological findings, renal function, serum albumin, and complement levels became normal, and DNA binding fell to 4-7%.
In December 1979 and throughout the following year she complained repeatedly of sternal and epigastric pain. In January 1981 malaise, weight loss, and bimodal fever reaching 40°C also developed. Examination revealed anaemia, sternal tenderness, 2 cm hepatomegaly, and 7 cm splenomegaly.
Investigations disclosed Bone marrow aspiration revealed a diagnosis of visceral leishmaniasis and showed a cellular marrow with a marked increase in macrophages, most containing Leishman-Donovan (LD) bodies (Fig. 1) multiplies in the reticuloendothelial system, including liver, spleen, and bone marrow. This accounts for the marked hepatosplenomegaly, pancytopenia, and probably the sternal pain, the latter antedating subsequent symptoms and signs by many months in this case. The exact nature of the immunological response evoked by the parasite is uncertain. The parasite multiplies unchecked despite the marked rise in IgG. This case illustrates immunosuppressive therapy uncovering occult leishmaniasis; appropriate therapy prevented a fatal outcome.
A febrile patient with SLE is a difficult clinical problem. The cause may be infection or exacerbation of disease activity. Fever, weight loss, pancytopenia, and splenomegaly are well documented in SLE. However, if the patient has visited an area endemic for visceral leishmaniasis, a diligent search for LD bodies may be necessary to exclude this disease.
Endemic areas are not confined to China and the tropics but include Southern France, Italy, Sicily, Spain, Malta, Greece, and Russia. 4 The disease has recently reached epidemic proportions in India with resurgence of the sandfly vector Phlebotomus argentipes following a reduction in the antimalarial spraying programmes.5 Travel to a from these areas is common, and untreated visceral leishmaniasis has a high mortality. Therefore doctors should remain aware of this disease, particularly in their immunosuppressed patients.
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